Oncostat

Oncostat

The recent revolution in –omics technology and the advent of targeted and immune therapies have increased the interest in molecular biomarkers capable of predicting the diagnostic, the clinical outcome of cancer patients or the response to specific therapies. The development of stratified medicine implies the segmentation of common cancers in small groups of tumors with specific abnormalities.

Lire la suite

Theme 1 "Clinical Trial Methodology" A new generation of clinical trial designs requiring repeated biomarker measurements and surrogate clinical endpoints is needed to evaluate treatment effects in trials with limited sample sizes.

Theme 2 "Meta-analysis of treatments and biomarkers” Large-scale collaborative individual patient data (IPD) meta-analyses are useful tools to provide high level of evidence on the efficacy and toxicity of anti-cancer therapies in molecularly defined strata .With the increasing number of therapies available for a specific indication in oncology, methods for network meta-analysis are being developed to compare their effectiveness.

Theme 3 "Economic evaluation of treatments and biomarkers" Because of the high costs associated with the tandem diagnostic and therapeutic medicine, economic analyses will be needed to evaluate the strategy associating the biomarkers with the molecularly targeted treatments, which represents a new field of research.

Theme 4 "Development and validation of biomarkers ".Once a potential biomarker has been identified for the prediction of diagnosis or clinical outcome of patients, an evidence-based evaluation implies careful replication in other cohorts. Advances in molecular genetics and in the knowledge of pathology of cancer are re-shaping the traditional methods in clinical epidemiology.

The Oncostat team is currently labelled Ligue Contre le Cancer (League Against Cancer).

The statistical software packages developed in the team are available to the scientific community on the website https://oncostat.github.io/

 

Localisation

Hôpital Gustave Roussy, Bat. B2M

114 rue Edouard Vaillant
94805 Villejuif


Principaux Financeurs
Inserm
INCA
IReSP
Union Européenne
NIH

Membres

Recrutement

Emploi Affectation Type Date En savoir plus
Biostatisticien H/F Oncostat Oncostat CDI- Temps Plein A partir de Lundi, juin 22, 2020 Consulter la fiche de poste

Dernières publications

Quality-of-Life Assessment in French Patients With Metastatic Melanoma in Real Life. M;Kandel, S;Dalle, A;Bardet, C;Allayous, L;Mortier, C;Dutriaux, B;Guillot, M;Leccia, S;Dalac, D;Legoupil, P;Saiag, H;Montaudie, JP;Arnault, F;B.Possenti, JJ;Grob, J;DeQuatrebarbes, M;Beylot-Barry, T;Lesimple, F;Aubin, E;Maubec, F;Granel-Brocard, PE;Stoebner, A;Dupuy, B;Dreno, S;Michiels, C;Lebbe, I;Borget. . 2020; : . doi:10.1002/cncr.32554
Article
[Prophylactic nodal radiotherapy in prostate cancer]. Bourdais, R.; Achkar, S.; Chauffert-Yvart, L.; Pasquier, D.; Sargos, P.; Blanchard, P.; Latorzeff, I.. Cancer Radiother. 2019; 23: p.688-695. doi:10.1016/j.canrad.2019.07.149
Article
Proton versus photon radiation-induced cell death in head and neck cancer cells. Wang, L.; Han, S.; Zhu, J.; Wang, X.; Li, Y.; Wang, Z.; Lin, E.; Wang, X.; Molkentine, D. P.; Blanchard, P.; Yang, Y.; Zhang, R.; Sahoo, N.; Gillin, M.; Zhu, X. R.; Zhang, X.; Myers, J. N.; Frank, S. J.. Head Neck. 2019; 41: p.46-55. doi:10.1002/hed.25357
Article
Nasopharyngeal carcinoma. Chen, Y. P.; Chan, A. T. C.; Le, Q. T.; Blanchard, P.; Sun, Y.; Ma, J.. Lancet. 2019; 394: p.64-80. doi:10.1016/s0140-6736(19)30956-0
Article
[Individualization of dose and fractionation of radiotherapy for head and neck cancers]. Blanchard, P.; Biau, J.; Castelli, J.; Tao, Y.; Graff, P.; Nguyen, F.. Cancer Radiother. 2019; 23: p.784-788. doi:10.1016/j.canrad.2019.07.131
Article

Thèses

Apport clinique des méta-analyses dans les cancers ORL localement avancés. Dirigée par Jean-Pierre Pignon & Pierre Blanchard. Lacas Benjamin. []: Paris Sud; .
Thesis
Incorporating historic information in multi-arm clinical trials for pediatric cancers. Abbas, Rachid. []: ; .
Thesis
Meta analyse des traitements néoadjuvants des cancers de l’œsophage et de la jonction oeso-gastrique. Faron Mathieu. []: ; .
Thesis
Essais cliniques randomisés en oncologie en présence de sous-types rares identifiés par biomarqueur. Dirigée par Stefan Michiels. Bayar Mohamed Amine. []: Paris Sud; .
Thesis
Identification de sous-groupes à l'aide de biomarqueurs de grande dimension dans les essais randomisés. Dirigée par Stefan Michiels & Federico Rotolo. Belhechmi Shaima . []: Paris Sud; .
Thesis
Coût et efficience des nouvelles stratégies thérapeutiques guidées par la biologie moléculaire en cancérologie. BAYLE Arnaud. []: ; .
Thesis
Méta-analyses sur données individuelles d’essais randomisés dans les cancers de l’estomac en situation avancée ou métastatique : Analyse de l’efficacité et de la toxicité de l’Irinotecan. . Chamseddine Ali. []: ; .
Thesis
Evaluation du coût et de la qualité de vie des patients atteints de mélanome métastatique : analyse des données de la cohorte MELBASE en vie réelle. Dirigée par Stefan Michiels & Isabelle Borget. Kandel Marguerite. []: Paris Sud; .
Thesis
Intégration de données multi-omiques pour la modélisation de l'impact de l'hétérogénéité inter-tumorale dans la survie de patients atteints de cancer. Rincourt, Sarah-Laure. []: Université Paris Saclay; .
Thesis
Méta-analyse en réseau et cancer ORL : utilité des critères de jugement multiples.. Claire Petit. []: ; .
Thesis